nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—GSTP1—urine—polycystic ovary syndrome	0.0234	0.0973	CbGeAlD
Clomipramine—CYP2C19—urine—polycystic ovary syndrome	0.0161	0.0671	CbGeAlD
Clomipramine—CYP1A2—urine—polycystic ovary syndrome	0.0132	0.0548	CbGeAlD
Clomipramine—HTR2A—urine—polycystic ovary syndrome	0.0103	0.0428	CbGeAlD
Clomipramine—CYP3A4—urine—polycystic ovary syndrome	0.00954	0.0397	CbGeAlD
Clomipramine—CYP2D6—urine—polycystic ovary syndrome	0.00939	0.039	CbGeAlD
Clomipramine—GSTP1—embryo—polycystic ovary syndrome	0.00756	0.0314	CbGeAlD
Clomipramine—HRH2—adrenal gland—polycystic ovary syndrome	0.00621	0.0258	CbGeAlD
Clomipramine—GSTP1—adrenal cortex—polycystic ovary syndrome	0.0062	0.0258	CbGeAlD
Clomipramine—GSTP1—endometrium—polycystic ovary syndrome	0.00554	0.023	CbGeAlD
Clomipramine—HRH2—endocrine gland—polycystic ovary syndrome	0.00539	0.0224	CbGeAlD
Clomipramine—HTR2B—adrenal cortex—polycystic ovary syndrome	0.00511	0.0212	CbGeAlD
Clomipramine—GSTP1—uterus—polycystic ovary syndrome	0.0051	0.0212	CbGeAlD
Clomipramine—GSTP1—pituitary gland—polycystic ovary syndrome	0.00501	0.0208	CbGeAlD
Clomipramine—GSTP1—adipose tissue—polycystic ovary syndrome	0.00499	0.0207	CbGeAlD
Clomipramine—HTR2B—endometrium—polycystic ovary syndrome	0.00456	0.019	CbGeAlD
Clomipramine—GSTP1—adrenal gland—polycystic ovary syndrome	0.00447	0.0186	CbGeAlD
Clomipramine—HTR2B—uterus—polycystic ovary syndrome	0.00421	0.0175	CbGeAlD
Clomipramine—GSTP1—female gonad—polycystic ovary syndrome	0.00417	0.0173	CbGeAlD
Clomipramine—GSTP1—vagina—polycystic ovary syndrome	0.00415	0.0172	CbGeAlD
Clomipramine—HTR2B—adipose tissue—polycystic ovary syndrome	0.00411	0.0171	CbGeAlD
Clomipramine—GSTP1—endocrine gland—polycystic ovary syndrome	0.00388	0.0161	CbGeAlD
Clomipramine—ALB—adrenal gland—polycystic ovary syndrome	0.00383	0.0159	CbGeAlD
Clomipramine—HTR2B—adrenal gland—polycystic ovary syndrome	0.00369	0.0153	CbGeAlD
Clomipramine—HTR2B—vagina—polycystic ovary syndrome	0.00342	0.0142	CbGeAlD
Clomipramine—HTR2A—embryo—polycystic ovary syndrome	0.00333	0.0138	CbGeAlD
Clomipramine—SLC6A2—adrenal gland—polycystic ovary syndrome	0.00328	0.0136	CbGeAlD
Clomipramine—SLC6A4—endocrine gland—polycystic ovary syndrome	0.00323	0.0134	CbGeAlD
Clomipramine—Contusion—Metformin—polycystic ovary syndrome	0.00312	0.0407	CcSEcCtD
Clomipramine—ADRA2A—endometrium—polycystic ovary syndrome	0.00287	0.0119	CbGeAlD
Clomipramine—CYP2C19—vagina—polycystic ovary syndrome	0.00286	0.0119	CbGeAlD
Clomipramine—SLC6A2—endocrine gland—polycystic ovary syndrome	0.00284	0.0118	CbGeAlD
Clomipramine—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00268	0.0111	CbGeAlD
Clomipramine—ADRA2A—uterus—polycystic ovary syndrome	0.00264	0.011	CbGeAlD
Clomipramine—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00259	0.0108	CbGeAlD
Clomipramine—ADRA2A—adipose tissue—polycystic ovary syndrome	0.00258	0.0107	CbGeAlD
Clomipramine—Neuropathy—Metformin—polycystic ovary syndrome	0.00255	0.0333	CcSEcCtD
Clomipramine—Propericiazine—ADRA1B—polycystic ovary syndrome	0.00254	0.0704	CrCbGaD
Clomipramine—ADRA2A—adrenal gland—polycystic ovary syndrome	0.00232	0.00963	CbGeAlD
Clomipramine—Ear pain—Metformin—polycystic ovary syndrome	0.00231	0.0302	CcSEcCtD
Clomipramine—HTR2A—pituitary gland—polycystic ovary syndrome	0.00221	0.00917	CbGeAlD
Clomipramine—CYP1A2—endocrine gland—polycystic ovary syndrome	0.00219	0.00908	CbGeAlD
Clomipramine—ABCB1—embryo—polycystic ovary syndrome	0.00218	0.00907	CbGeAlD
Clomipramine—ADRA2A—female gonad—polycystic ovary syndrome	0.00216	0.00898	CbGeAlD
Clomipramine—ADRA2A—vagina—polycystic ovary syndrome	0.00215	0.00893	CbGeAlD
Clomipramine—ADRA2A—endocrine gland—polycystic ovary syndrome	0.00201	0.00835	CbGeAlD
Clomipramine—HTR2A—adrenal gland—polycystic ovary syndrome	0.00197	0.00819	CbGeAlD
Clomipramine—Migraine—Metformin—polycystic ovary syndrome	0.00194	0.0254	CcSEcCtD
Clomipramine—Dehydration—Metformin—polycystic ovary syndrome	0.00184	0.024	CcSEcCtD
Clomipramine—HTR2A—vagina—polycystic ovary syndrome	0.00183	0.00759	CbGeAlD
Clomipramine—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00179	0.00744	CbGeAlD
Clomipramine—Breast disorder—Metformin—polycystic ovary syndrome	0.00178	0.0233	CcSEcCtD
Clomipramine—HTR2A—endocrine gland—polycystic ovary syndrome	0.00171	0.0071	CbGeAlD
Clomipramine—CYP2D6—female gonad—polycystic ovary syndrome	0.00167	0.00696	CbGeAlD
Clomipramine—Sweating increased—Metformin—polycystic ovary syndrome	0.00166	0.0217	CcSEcCtD
Clomipramine—Acepromazine—ADRA1B—polycystic ovary syndrome	0.00163	0.0452	CrCbGaD
Clomipramine—Thioproperazine—ADRA1B—polycystic ovary syndrome	0.0016	0.0442	CrCbGaD
Clomipramine—ABCB1—endometrium—polycystic ovary syndrome	0.0016	0.00664	CbGeAlD
Clomipramine—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00158	0.00658	CbGeAlD
Clomipramine—CYP2D6—endocrine gland—polycystic ovary syndrome	0.00156	0.00647	CbGeAlD
Clomipramine—Propiomazine—ADRA1D—polycystic ovary syndrome	0.00153	0.0424	CrCbGaD
Clomipramine—Drowsiness—Metformin—polycystic ovary syndrome	0.00152	0.0199	CcSEcCtD
Clomipramine—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00149	0.0195	CcSEcCtD
Clomipramine—ABCB1—uterus—polycystic ovary syndrome	0.00147	0.00612	CbGeAlD
Clomipramine—ABCB1—pituitary gland—polycystic ovary syndrome	0.00145	0.00601	CbGeAlD
Clomipramine—ABCB1—adipose tissue—polycystic ovary syndrome	0.00144	0.00598	CbGeAlD
Clomipramine—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00144	0.0188	CcSEcCtD
Clomipramine—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.00142	0.0394	CrCbGaD
Clomipramine—Bradycardia—Metformin—polycystic ovary syndrome	0.00139	0.0182	CcSEcCtD
Clomipramine—Rhinitis—Metformin—polycystic ovary syndrome	0.00137	0.0179	CcSEcCtD
Clomipramine—Hepatitis—Metformin—polycystic ovary syndrome	0.00137	0.0178	CcSEcCtD
Clomipramine—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00136	0.0177	CcSEcCtD
Clomipramine—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00134	0.0175	CcSEcCtD
Clomipramine—Methotrimeprazine—ADRA1D—polycystic ovary syndrome	0.00131	0.0362	CrCbGaD
Clomipramine—Propiomazine—ADRA1B—polycystic ovary syndrome	0.00131	0.0362	CrCbGaD
Clomipramine—ABCB1—adrenal gland—polycystic ovary syndrome	0.00129	0.00537	CbGeAlD
Clomipramine—Doxepin—ADRA1D—polycystic ovary syndrome	0.00128	0.0353	CrCbGaD
Clomipramine—Eye disorder—Metformin—polycystic ovary syndrome	0.00128	0.0167	CcSEcCtD
Clomipramine—Flushing—Metformin—polycystic ovary syndrome	0.00127	0.0165	CcSEcCtD
Clomipramine—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00127	0.0165	CcSEcCtD
Clomipramine—Angiopathy—Metformin—polycystic ovary syndrome	0.00124	0.0162	CcSEcCtD
Clomipramine—Immune system disorder—Metformin—polycystic ovary syndrome	0.00123	0.0161	CcSEcCtD
Clomipramine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00123	0.0161	CcSEcCtD
Clomipramine—Chills—Metformin—polycystic ovary syndrome	0.00123	0.016	CcSEcCtD
Clomipramine—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.00121	0.0336	CrCbGaD
Clomipramine—ABCB1—female gonad—polycystic ovary syndrome	0.0012	0.005	CbGeAlD
Clomipramine—ABCB1—vagina—polycystic ovary syndrome	0.0012	0.00497	CbGeAlD
Clomipramine—Malnutrition—Metformin—polycystic ovary syndrome	0.00119	0.0155	CcSEcCtD
Clomipramine—Flatulence—Metformin—polycystic ovary syndrome	0.00117	0.0153	CcSEcCtD
Clomipramine—Thioridazine—ADRA1B—polycystic ovary syndrome	0.00117	0.0324	CrCbGaD
Clomipramine—Dysgeusia—Metformin—polycystic ovary syndrome	0.00116	0.0152	CcSEcCtD
Clomipramine—Trimipramine—ADRA1B—polycystic ovary syndrome	0.00114	0.0316	CrCbGaD
Clomipramine—Muscle spasms—Metformin—polycystic ovary syndrome	0.00114	0.0149	CcSEcCtD
Clomipramine—Promazine—ADRA1D—polycystic ovary syndrome	0.00114	0.0314	CrCbGaD
Clomipramine—Vision blurred—Metformin—polycystic ovary syndrome	0.00112	0.0146	CcSEcCtD
Clomipramine—ABCB1—endocrine gland—polycystic ovary syndrome	0.00112	0.00465	CbGeAlD
Clomipramine—Methotrimeprazine—ADRA1B—polycystic ovary syndrome	0.00112	0.0309	CrCbGaD
Clomipramine—Tremor—Metformin—polycystic ovary syndrome	0.00111	0.0145	CcSEcCtD
Clomipramine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.0011	0.0144	CcSEcCtD
Clomipramine—Acepromazine—ADRA1A—polycystic ovary syndrome	0.0011	0.0304	CrCbGaD
Clomipramine—Doxepin—ADRA1B—polycystic ovary syndrome	0.00109	0.0301	CrCbGaD
Clomipramine—Thioproperazine—ADRA1A—polycystic ovary syndrome	0.00108	0.0298	CrCbGaD
Clomipramine—Malaise—Metformin—polycystic ovary syndrome	0.00107	0.014	CcSEcCtD
Clomipramine—Syncope—Metformin—polycystic ovary syndrome	0.00107	0.0139	CcSEcCtD
Clomipramine—Palpitations—Metformin—polycystic ovary syndrome	0.00105	0.0137	CcSEcCtD
Clomipramine—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00105	0.0136	CcSEcCtD
Clomipramine—Hypertension—Metformin—polycystic ovary syndrome	0.00103	0.0134	CcSEcCtD
Clomipramine—Chest pain—Metformin—polycystic ovary syndrome	0.00101	0.0132	CcSEcCtD
Clomipramine—Myalgia—Metformin—polycystic ovary syndrome	0.00101	0.0132	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00101	0.0131	CcSEcCtD
Clomipramine—Discomfort—Metformin—polycystic ovary syndrome	0.001	0.0131	CcSEcCtD
Clomipramine—Imipramine—ADRA1D—polycystic ovary syndrome	0.000994	0.0275	CrCbGaD
Clomipramine—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.000988	0.0273	CrCbGaD
Clomipramine—Oedema—Metformin—polycystic ovary syndrome	0.000971	0.0127	CcSEcCtD
Clomipramine—Promazine—ADRA1B—polycystic ovary syndrome	0.000969	0.0268	CrCbGaD
Clomipramine—Shock—Metformin—polycystic ovary syndrome	0.000955	0.0125	CcSEcCtD
Clomipramine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000952	0.0124	CcSEcCtD
Clomipramine—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00095	0.0124	CcSEcCtD
Clomipramine—Skin disorder—Metformin—polycystic ovary syndrome	0.000943	0.0123	CcSEcCtD
Clomipramine—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000938	0.0122	CcSEcCtD
Clomipramine—Anorexia—Metformin—polycystic ovary syndrome	0.000925	0.0121	CcSEcCtD
Clomipramine—Hypotension—Metformin—polycystic ovary syndrome	0.000907	0.0118	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000884	0.0115	CcSEcCtD
Clomipramine—Propiomazine—ADRA1A—polycystic ovary syndrome	0.00088	0.0243	CrCbGaD
Clomipramine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000872	0.0114	CcSEcCtD
Clomipramine—Dyspnoea—Metformin—polycystic ovary syndrome	0.000865	0.0113	CcSEcCtD
Clomipramine—Somnolence—Metformin—polycystic ovary syndrome	0.000863	0.0113	CcSEcCtD
Clomipramine—Dyspepsia—Metformin—polycystic ovary syndrome	0.000854	0.0112	CcSEcCtD
Clomipramine—Chlorpromazine—ADRA1B—polycystic ovary syndrome	0.000852	0.0236	CrCbGaD
Clomipramine—Imipramine—ADRA1B—polycystic ovary syndrome	0.000848	0.0235	CrCbGaD
Clomipramine—Decreased appetite—Metformin—polycystic ovary syndrome	0.000844	0.011	CcSEcCtD
Clomipramine—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.000843	0.0233	CrCbGaD
Clomipramine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000838	0.0109	CcSEcCtD
Clomipramine—Fatigue—Metformin—polycystic ovary syndrome	0.000837	0.0109	CcSEcCtD
Clomipramine—Constipation—Metformin—polycystic ovary syndrome	0.00083	0.0108	CcSEcCtD
Clomipramine—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.000817	0.0226	CrCbGaD
Clomipramine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0008	0.0104	CcSEcCtD
Clomipramine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000794	0.0104	CcSEcCtD
Clomipramine—Thioridazine—ADRA1A—polycystic ovary syndrome	0.000788	0.0218	CrCbGaD
Clomipramine—Urticaria—Metformin—polycystic ovary syndrome	0.000771	0.0101	CcSEcCtD
Clomipramine—Trimipramine—ADRA1A—polycystic ovary syndrome	0.00077	0.0213	CrCbGaD
Clomipramine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000767	0.01	CcSEcCtD
Clomipramine—Methotrimeprazine—ADRA1A—polycystic ovary syndrome	0.000752	0.0208	CrCbGaD
Clomipramine—Promethazine—ADRA1A—polycystic ovary syndrome	0.000741	0.0205	CrCbGaD
Clomipramine—Doxepin—ADRA1A—polycystic ovary syndrome	0.000734	0.0203	CrCbGaD
Clomipramine—Trifluoperazine—ADRA1A—polycystic ovary syndrome	0.000731	0.0202	CrCbGaD
Clomipramine—Asthenia—Metformin—polycystic ovary syndrome	0.000696	0.00909	CcSEcCtD
Clomipramine—Pruritus—Metformin—polycystic ovary syndrome	0.000687	0.00896	CcSEcCtD
Clomipramine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000664	0.00867	CcSEcCtD
Clomipramine—Promazine—ADRA1A—polycystic ovary syndrome	0.000652	0.018	CrCbGaD
Clomipramine—Dizziness—Metformin—polycystic ovary syndrome	0.000642	0.00838	CcSEcCtD
Clomipramine—Vomiting—Metformin—polycystic ovary syndrome	0.000617	0.00806	CcSEcCtD
Clomipramine—Rash—Metformin—polycystic ovary syndrome	0.000612	0.00799	CcSEcCtD
Clomipramine—Dermatitis—Metformin—polycystic ovary syndrome	0.000611	0.00798	CcSEcCtD
Clomipramine—Headache—Metformin—polycystic ovary syndrome	0.000608	0.00794	CcSEcCtD
Clomipramine—Nausea—Metformin—polycystic ovary syndrome	0.000577	0.00753	CcSEcCtD
Clomipramine—Chlorpromazine—ADRA1A—polycystic ovary syndrome	0.000574	0.0159	CrCbGaD
Clomipramine—Imipramine—ADRA1A—polycystic ovary syndrome	0.000571	0.0158	CrCbGaD
Clomipramine—Amitriptyline—ADRA1A—polycystic ovary syndrome	0.000567	0.0157	CrCbGaD
Clomipramine—Desipramine—ADRB2—polycystic ovary syndrome	0.0004	0.0111	CrCbGaD
Clomipramine—HRH2—Signaling Pathways—IRS1—polycystic ovary syndrome	5.61e-05	8.67e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.57e-05	8.61e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	5.53e-05	8.55e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	5.51e-05	8.53e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	5.5e-05	8.51e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.49e-05	8.49e-05	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	5.47e-05	8.45e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—YAP1—polycystic ovary syndrome	5.42e-05	8.38e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	5.42e-05	8.38e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—POMC—polycystic ovary syndrome	5.4e-05	8.35e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—IGF1—polycystic ovary syndrome	5.4e-05	8.34e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—AKT2—polycystic ovary syndrome	5.39e-05	8.34e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	5.38e-05	8.32e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—INS—polycystic ovary syndrome	5.37e-05	8.31e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	5.36e-05	8.29e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.35e-05	8.27e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NRG1—polycystic ovary syndrome	5.25e-05	8.12e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	5.24e-05	8.11e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	5.21e-05	8.06e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	5.21e-05	8.06e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—NAMPT—polycystic ovary syndrome	5.21e-05	8.06e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NGFR—polycystic ovary syndrome	5.2e-05	8.04e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IGF1—polycystic ovary syndrome	5.19e-05	8.03e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AKT2—polycystic ovary syndrome	5.19e-05	8.03e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.18e-05	8.01e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	5.16e-05	7.99e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	5.15e-05	7.96e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	5.15e-05	7.96e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	5.14e-05	7.96e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	5.13e-05	7.94e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	5.13e-05	7.93e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	5.13e-05	7.93e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	5.12e-05	7.92e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	5.11e-05	7.91e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.11e-05	7.9e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	5.1e-05	7.89e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	5.09e-05	7.87e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.07e-05	7.84e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	5.05e-05	7.82e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	5.05e-05	7.81e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	5.02e-05	7.76e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.96e-05	7.68e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.94e-05	7.64e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.93e-05	7.63e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	4.93e-05	7.62e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IRS2—polycystic ovary syndrome	4.93e-05	7.62e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	4.89e-05	7.56e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.89e-05	7.56e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	4.87e-05	7.53e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	4.87e-05	7.52e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	4.86e-05	7.51e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—LEP—polycystic ovary syndrome	4.82e-05	7.46e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	4.8e-05	7.42e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	4.8e-05	7.42e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	4.79e-05	7.41e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	4.78e-05	7.4e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.77e-05	7.37e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	4.75e-05	7.35e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.75e-05	7.34e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	4.68e-05	7.23e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	4.66e-05	7.21e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	4.66e-05	7.21e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	4.66e-05	7.21e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.65e-05	7.19e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	4.64e-05	7.18e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	4.64e-05	7.18e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	4.62e-05	7.14e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.58e-05	7.09e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	4.56e-05	7.06e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	4.56e-05	7.05e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	4.53e-05	7.01e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	4.51e-05	6.98e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	4.51e-05	6.97e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IRS2—polycystic ovary syndrome	4.5e-05	6.96e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.49e-05	6.95e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.48e-05	6.93e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	4.48e-05	6.92e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.47e-05	6.92e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	4.47e-05	6.91e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	4.45e-05	6.88e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	4.41e-05	6.83e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—LEP—polycystic ovary syndrome	4.4e-05	6.81e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	4.36e-05	6.74e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.34e-05	6.71e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.32e-05	6.68e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.32e-05	6.67e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.31e-05	6.67e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IRS1—polycystic ovary syndrome	4.3e-05	6.65e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	4.3e-05	6.65e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	4.29e-05	6.64e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	4.28e-05	6.62e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	4.26e-05	6.58e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	4.25e-05	6.57e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.24e-05	6.56e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	4.24e-05	6.55e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	4.19e-05	6.48e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—POMC—polycystic ovary syndrome	4.14e-05	6.41e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—TH—polycystic ovary syndrome	4.14e-05	6.4e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	4.14e-05	6.4e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—INS—polycystic ovary syndrome	4.12e-05	6.37e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	4.11e-05	6.35e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	4.08e-05	6.31e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	4.08e-05	6.31e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	4.07e-05	6.29e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	4.06e-05	6.28e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	4.03e-05	6.22e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	4.01e-05	6.2e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IGF1—polycystic ovary syndrome	3.98e-05	6.16e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	3.98e-05	6.16e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—IL6—polycystic ovary syndrome	3.97e-05	6.14e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	3.95e-05	6.11e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	3.95e-05	6.1e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	3.93e-05	6.08e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.93e-05	6.08e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.93e-05	6.07e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.92e-05	6.06e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	3.87e-05	5.98e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.86e-05	5.97e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	3.79e-05	5.86e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	3.78e-05	5.85e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.78e-05	5.85e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	3.78e-05	5.85e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	3.76e-05	5.81e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.75e-05	5.8e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—TH—polycystic ovary syndrome	3.71e-05	5.74e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.68e-05	5.69e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	3.64e-05	5.63e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.64e-05	5.62e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.63e-05	5.62e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	3.63e-05	5.61e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TH—polycystic ovary syndrome	3.63e-05	5.61e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.62e-05	5.6e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	3.61e-05	5.59e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	3.6e-05	5.57e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.6e-05	5.57e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	3.6e-05	5.56e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	3.58e-05	5.53e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.57e-05	5.52e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	3.55e-05	5.49e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	3.53e-05	5.45e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	3.52e-05	5.45e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.52e-05	5.44e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.45e-05	5.34e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TH—polycystic ovary syndrome	3.42e-05	5.28e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.41e-05	5.27e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.41e-05	5.27e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	3.4e-05	5.25e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	3.4e-05	5.25e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.39e-05	5.25e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GNAS—polycystic ovary syndrome	3.38e-05	5.22e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	3.35e-05	5.18e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	3.35e-05	5.17e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	3.32e-05	5.14e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	3.32e-05	5.13e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—NCOR1—polycystic ovary syndrome	3.22e-05	4.98e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.17e-05	4.9e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.15e-05	4.87e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.14e-05	4.85e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.12e-05	4.83e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.08e-05	4.77e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	3.05e-05	4.72e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	3.05e-05	4.72e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	3.05e-05	4.71e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.04e-05	4.7e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	3.03e-05	4.69e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	3.03e-05	4.69e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.96e-05	4.58e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	2.93e-05	4.54e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	2.93e-05	4.53e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.93e-05	4.53e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	2.92e-05	4.52e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.89e-05	4.48e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	2.89e-05	4.47e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	2.88e-05	4.46e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	2.87e-05	4.43e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	2.87e-05	4.43e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—MTHFR—polycystic ovary syndrome	2.84e-05	4.4e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.82e-05	4.36e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.82e-05	4.35e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.81e-05	4.35e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	2.81e-05	4.34e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	2.79e-05	4.31e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.79e-05	4.31e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.78e-05	4.3e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.78e-05	4.29e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.75e-05	4.25e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	2.74e-05	4.23e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.67e-05	4.13e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	2.66e-05	4.11e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.65e-05	4.1e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.65e-05	4.09e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	2.63e-05	4.07e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.62e-05	4.06e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.6e-05	4.02e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.58e-05	3.99e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	2.55e-05	3.95e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.55e-05	3.94e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.55e-05	3.94e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	2.52e-05	3.9e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	2.5e-05	3.87e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.49e-05	3.85e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.42e-05	3.74e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.41e-05	3.73e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.4e-05	3.71e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.38e-05	3.67e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.36e-05	3.65e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.35e-05	3.63e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL6—polycystic ovary syndrome	2.35e-05	3.63e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.32e-05	3.58e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.32e-05	3.58e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PPARG—polycystic ovary syndrome	2.31e-05	3.57e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—POMC—polycystic ovary syndrome	2.27e-05	3.52e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—INS—polycystic ovary syndrome	2.26e-05	3.5e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.25e-05	3.48e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.24e-05	3.47e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.23e-05	3.45e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.2e-05	3.4e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.17e-05	3.36e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	2.13e-05	3.3e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	2.07e-05	3.2e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.04e-05	3.16e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	2.04e-05	3.16e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—INS—polycystic ovary syndrome	2.03e-05	3.14e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.02e-05	3.12e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.99e-05	3.08e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.99e-05	3.08e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.98e-05	3.06e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.95e-05	3.01e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.92e-05	2.96e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	1.9e-05	2.94e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	1.88e-05	2.9e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—INS—polycystic ovary syndrome	1.87e-05	2.89e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.82e-05	2.82e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	1.8e-05	2.78e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	1.77e-05	2.74e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.74e-05	2.69e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.66e-05	2.57e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.65e-05	2.55e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.64e-05	2.54e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.61e-05	2.49e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.59e-05	2.46e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.58e-05	2.45e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.54e-05	2.37e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.51e-05	2.34e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.33e-05	2.05e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.24e-05	1.93e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.23e-05	1.9e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.22e-05	1.89e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.15e-05	1.78e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.05e-05	1.62e-05	CbGpPWpGaD
